DETERMINATION OF THE ACUTE TOXICITY (LD50) OF A GLYCYRRHETINIC ACID DERIVATIVE IN MICE: AN IMRAD-BASED ANALYTICAL ARTICLE USING SIX PEER-REVIEWED STUDIES WITH VERIFIED DOI NUMBERS
;
Acute toxicity testing is the earliest systematic in vivo toxicological step in preclinical drug evaluation. Historically, the LD50 value—the dose that causes death in 50% of treated animals—served as the central quantitative indicator of acute toxicity. Although modern ethical toxicology increasingly emphasizes fixed-dose and up-and-down approaches rather than large classical LD50 designs, the LD50 concept remains highly relevant in pharmacological dissertations and in the interpretation of older literatureAbstrak
Acute toxicity assessment remains the first indispensable in vivo step in the preclinical development of semisynthetic glycyrrhetinic acid (GA) derivatives. Determination of the median lethal dose (LD50) in mice, together with close observation of behavioral, autonomic, neurological, biochemical, and histopathological signs of intoxication, provides the toxicological basis for selecting pharmacologically relevant dose ranges for subsequent anti-inflammatory, antitumor, hepatoprotective, or antimicrobial studies. The aim of the present article was to prepare an IMRAD-format analytical paper on the topic “Determination of the acute toxicity (LD50) of a glycyrrhetinic acid derivative in mice” using six original or primary-source peer-reviewed publications and safety papers with real and verifiable DOI numbers. The paper was designed not as a fictional experimental report but as a dissertation-oriented analytical model showing how an acute-toxicity study of a glycyrrhetinic acid derivative should be justified, structured, interpreted, and connected with the wider glycyrrhetinic acid literature.
Iqtiboslar
Finney R.S.H., Somers G.F., Wilkinson J.H. The pharmacological properties of glycyrrhetinic acid—a new anti-inflammatory drug. Journal of Pharmacy and Pharmacology. 1958;10(1):687–695. DOI: 10.1111/j.2042-7158.1958.tb10361.x.
Andersen F.A. Final Report on the Safety Assessment of Glycyrrhetinic Acid, Potassium Glycyrrhetinate, Disodium Succinoyl Glycyrrhetinate, Glyceryl Glycyrrhetinate, Glycyrrhetinyl Stearate, Stearyl Glycyrrhetinate, Glycyrrhizic Acid, Ammonium Glycyrrhizate, Dipotassium Glycyrrhizate, Disodium Glycyrrhizate, Trisodium Glycyrrhizate, Methyl Glycyrrhizate, and Potassium Glycyrrhizinate. International Journal of Toxicology. 2007;26(Suppl 2):79–112. DOI: 10.1080/10915810701351228.
Mahmoud A.M., Al Dera H.S. 18β-Glycyrrhetinic acid exerts protective effects against cyclophosphamide-induced hepatotoxicity: potential role of PPARγ and Nrf2 upregulation. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2015;388:829–837. DOI: 10.1007/s00210-015-1134-0.
Lv Q.-L., Wang G.-H., Chen S.-H., Hu L., Zhang X., Ying G., Qin C.-Z., Zhou H.-H. In Vitro and in Vivo Inhibitory Effects of Glycyrrhetinic Acid in Mice and Human Cytochrome P450 3A4. International Journal of Environmental Research and Public Health. 2016;13(1):84. DOI: 10.3390/ijerph13010084.
Markov A.V., Sen’kova A.V., Zenkova M.A., Logashenko E.B. Novel Glycyrrhetinic Acid Derivative Soloxolone Methyl Inhibits the Inflammatory Response and Tumor Growth in vivo. Molecular Biology. 2018;52(2):306–313. DOI: 10.7868/S0026898418020143.
##submission.downloads##
Nashr qilingan
Nashr
Bo'lim
Iqtibos keltirish tartibi
